T-cadherin (Cdh13) in association with pancreatic β-cell granules contributes to second phase insulin secretion.
Tyrberg B, Miles P, Azizian KT, Denzel MS, Nieves ML, Monosov EZ, Levine F, Ranscht B
Islets. 2011 Nov-Dec;3(6):327-37
Growth hormone increases beta-cell proliferation in transplanted human and fetal rat islets.
Höglund E, Mattsson G, Tyrberg B, Andersson A, Carlsson C
HES6 reverses nuclear reprogramming of insulin-producing cells following cell fusion.
Ball AJ, Abrahamsson AE, Tyrberg B, Itkin-Ansari P, Levine F
Biochem Biophys Res Commun. 2007 Apr 6;355(2):331-7
Basic helix-loop-helix gene Hes6 delineates the sensory hair cell lineage in the inner ear.
Qian D, Radde-Gallwitz K, Kelly M, Tyrberg B, Kim J, Gao WQ, Chen P
Dev Dyn. 2006 Jun;235(6):1689-700
Beta-cell differentiation from nonendocrine epithelial cells of the adult human pancreas.
Hao E, Tyrberg B, Itkin-Ansari P, Lakey JR, Geron I, Monosov EZ, Barcova M, Mercola M, Levine F
Nat Med. 2006 Mar;12(3):310-6
Islet expression of the DNA repair enzyme 8-oxoguanosine DNA glycosylase (Ogg1) in human type 2 diabetes.
Tyrberg B, Anachkov KA, Dib SA, Wang-Rodriguez J, Yoon KH, Levine F
BMC Endocr Disord. 2002 Apr 25;2(1):2
Current and future treatment strategies for type 2 diabetes: the beta-cell as a therapeutic target.
Tyrberg B, Levine F
Curr Opin Investig Drugs. 2001 Nov;2(11):1568-74
Species differences in susceptibility of transplanted and cultured pancreatic islets to the beta-cell toxin alloxan.
Tyrberg B, Andersson A, Borg LA
Gen Comp Endocrinol. 2001 Jun;122(3):238-51
Stimulated endocrine cell proliferation and differentiation in transplanted human pancreatic islets: effects of the ob gene and compensatory growth of the implantation organ.
Tyrberg B, Ustinov J, Otonkoski T, Andersson A
Diabetes. 2001 Feb;50(2):301-7
Human islets in mixed islet grafts protect mouse pancreatic beta-cells from alloxan toxicity.
Tyrberg B, Eizirik DL, Marklund SL, Olejnicka B, Madsen OD, Andersson A
Pharmacol Toxicol. 1999 Dec;85(6):269-75
Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes.
Flodström M, Tyrberg B, Eizirik DL, Sandler S
Diabetes. 1999 Apr;48(4):706-13
View All Publications
Artificial sweeteners stimulate adipogenesis and suppress lipolysis independent of sweet taste receptors.
Simon BR, Parlee SD, Learman BS, Mori H, Scheller EL, Cawthorn WP, Ning X, Gallagher K, Tyrberg B, Assadi-Porter FM, Evans CR, Macdougald OA
J Biol Chem. 2013 Sep 24;
Björn Tyrberg's Research Focus
Type 1 Diabetes, Type 2 Diabetes, Diabetes - General, Metabolic Diseases, Obesity
The global incidence of diabetes is increasing in epidemic proportions, particularly obesity-related type 2 diabetes. Complications from diabetes are severe and at present no cure exists. Today, Type 2 diabetes is recognized as a ß-cell disease as much as a disease of insulin target organs, and it has become more and more evident that maintenance of the functional ß-cell mass, i.e. the sum of insulin secretion and the number of available ß-cells, plays a central role.
Dr. Tyrberg's research focuses on understanding how functional ß-cell mass homeostasis is regulated after birth, both under normal circumstances and during diabetes. Previous work demonstrated that human ß-cells renew both through self-replication and through differentiation from progenitor cells, as well as addressed mechanisms of ß-cell death in type 1 and type 2 diabetes. Current efforts focus on acute and chronic nutrient regulation of ß-cell insulin secretion, survival and proliferation through a novel group of G-protein coupled receptors discovered in the lab. Our technical arsenal includes for example advanced live-cell imaging techniques, such as TIRF, FRET and ratiometric calcium-imaging of ß-cells and islets of Langerhans, small-molecule probe discovery and whole animal physiology.
About Björn Tyrberg
Björn P. Tyrberg was born in Sweden. He received his Master of Science in Pharmacy in 1995 from Uppsala University in Sweden. He joined the laboratory of Drs. Claes Hellerström and Arne Andersson the same year and received his Doctorate in Medical Sciences in 1999, also from Uppsala University. He received postdoctoral training in the laboratories of Dr. Fred Levine at University of California San Diego and Drs. Barbara Ranscht and Evan Snyder at Sanford-Burnham Medical Research Institute. Dr. Tyrberg was appointed to faculty at the Diabetes and Obesity Research Center in 2007.
Dr. Tyrberg is a Principal Investigator in BetaBat (a collaborative project funded by the European Commission under the 7th Framework Programme) with the goals to develop novel treatment strategies based on knowledge of cellular dysfunction in diabetes (http://betabat.ulb.ac.be/). The Tyrberg lab and Sanford-Burnham role is to provide small molecule high-throughput screening services and expertise to consortium partners.
Doctor of Medical Sciences (PhD), Uppsala University, Sweden, 1999
Licensed Pharmacist, European Union, 1999
Master of Science in Pharmacy, Uppsala University, Sweden, 1995
Courtesy Assistant Professor, Department of Pathology, University of Florida